Following that, although another traditional pairwise meta-analysis specifically focused on colorectal tumors, the authors were still limited to a methodology restriction, which was to pool all medications with different mechanisms into one group, and achieved results that overall GLP-1 receptor agonists did not significantly increase the colorectal tumor risk without specific information regarding individual medications[28]. Here, GLP1R is linked to colorectal neoplasm.